Literature DB >> 27056876

Vonoprazan Helicobacter pylori eradication therapy: ethical and interpretation issues.

David Y Graham.   

Abstract

Entities:  

Keywords:  ANTIBIOTIC THERAPY; CLINICAL TRIALS; HELICOBACTER PYLORI

Mesh：

Substances：

Year:  2016        PMID： 27056876      PMCID： PMC6916723          DOI： 10.1136/gutjnl-2016-311796

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  4 in total

1.  Hp-normogram (normo-graham) for Assessing the Outcome of H. pylori Therapy: Effect of Resistance, Duration, and CYP2C19 Genotype.

Authors:  David Y Graham
Journal:  Helicobacter       Date:  2015-11-27       Impact factor: 5.753

2.  Editorial--Avoiding Unethical Helicobacter pylori Clinical Trials: Susceptibility-Based Studies and Probiotics as Adjuvants.

Authors:  David Y Graham
Journal:  Helicobacter       Date:  2015-06-30       Impact factor: 5.753

Review 3.  Role of bismuth in improving Helicobacter pylori eradication with triple therapy.

Authors:  Maria Pina Dore; Hong Lu; David Y Graham
Journal:  Gut       Date:  2016-02-04       Impact factor: 23.059

4.  Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.

Authors:  Kazunari Murakami; Yuuichi Sakurai; Madoka Shiino; Nobuo Funao; Akira Nishimura; Masahiro Asaka
Journal:  Gut       Date:  2016-03-02       Impact factor: 23.059
  4 in total
  9 in total

Review 1.  Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Multicenter Study and a Review of the Literature.

Authors:  Hiroki Tanabe; Katsuyoshi Ando; Kiichi Sato; Takahiro Ito; Mitsuru Goto; Tomonobu Sato; Akihiro Fujinaga; Toru Kawamoto; Tatsuya Utsumi; Nobuyuki Yanagawa; Eiichiro Ichiishi; Takaaki Otake; Yutaka Kohgo; Yoshiki Nomura; Nobuhiro Ueno; Hiroko Sugano; Shin Kashima; Kentaro Moriichi; Mikihiro Fujiya; Toshikatsu Okumura
Journal:  Dig Dis Sci       Date:  2017-06-29       Impact factor: 3.199

Review 2.  Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases.

Authors:  Xiaoxiao Yang; Yueyue Li; Yiyuan Sun; Mingming Zhang; Chuanguo Guo; Iqtida Ahmed Mirza; Yan-Qing Li
Journal:  Dig Dis Sci       Date:  2017-12-27       Impact factor: 3.199

Review 3.  Treating Helicobacter pylori effectively while minimizing misuse of antibiotics.

Authors:  Akiko Shiotani; Hong Lu; Maria Pina Dore; David Y Graham
Journal:  Cleve Clin J Med       Date:  2017-04       Impact factor: 2.321

Review 4.  Vonoprazan-based therapy for Helicobacter pylori eradication: experience and clinical evidence.

Authors:  Yuko Akazawa; Daisuke Fukuda; Yutaka Fukuda
Journal:  Therap Adv Gastroenterol       Date:  2016-09-22       Impact factor: 4.409

5.  Safety of first-line triple therapy with a potassium-competitive acid blocker for Helicobacter pylori eradication in children.

Authors:  Chika Kusano; Takuji Gotoda; Sho Suzuki; Hisatomo Ikehara; Mitsuhiko Moriyama
Journal:  J Gastroenterol       Date:  2017-11-07       Impact factor: 7.527

6.  Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance.

Authors:  Hiroshi Matsumoto; Akiko Shiotani; Ryo Katsumata; Minoru Fujita; Rui Nakato; Takahisa Murao; Manabu Ishii; Tomoari Kamada; Ken Haruma; David Y Graham
Journal:  Dig Dis Sci       Date:  2016-09-22       Impact factor: 3.199

Review 7.  Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance.

Authors:  Yi Hu; Yin Zhu; Nong-Hua Lu
Journal:  Front Cell Infect Microbiol       Date:  2017-05-05       Impact factor: 5.293

Review 8.  Helicobacter pylori diagnosis and therapy in the era of antimicrobial stewardship.

Authors:  Akiko Shiotani; Priya Roy; Hong Lu; David Y Graham
Journal:  Therap Adv Gastroenterol       Date:  2021-12-21       Impact factor: 4.409

9.  Clinical Effect of Clarithromycin Combined with Tinidazole on Helicobacter pylori-Related Gastritis and Its Influence on COX-2 Expression.

Authors:  Chenxi He; Fanting Kong; Xinying Zhu; Fanlei Kong; Wei Zhao; Yanling Liu; Kuixiang Wang
Journal:  Biomed Res Int       Date:  2021-11-30       Impact factor: 3.411
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.